<p>Replimune Group, Inc.（納斯達克代碼：REPL - 獲取免費報告）在週五的交易中下跌了 5.9%。該公司的股價最低曾達到 8.91 美元，最後交易價為 8.82 美元。在午盤交易中，共成交了 86,686 股，較平均交易量 931,113 股下降了 91%。該股票此前收盤價為 9.37 美元。</p>
<p>獲取 <strong>Replimune Group</strong> 的提醒：</p>
<h2>分析師設定新的價格目標</h2>
<p>多位股票分析師最近對該公司發表了評論。HC Wainwright 將 Replimune Group 的價格目標從 21.00 美元上調至 22.00 美元，並在 2 月 13 日的報告中給予該股票 “買入” 評級。摩根大通將 Replimune Group 的股票目標價從 16.00 美元上調至 18.00 美元，並在 2 月 26 日的研究報告中給予該公司 “增持” 評級。七位投資分析師對該股票給予了買入評級，一位分析師給予了強烈買入評級。根據 MarketBeat 的數據，該公司的共識評級為 “買入”，平均價格目標為 19.43 美元。</p>
<p><strong>查看我們對 REPL 的最新分析</strong></p>
<h2>Replimune Group 股票下跌 6.8%</h2>
<p>該股票的市值為 6.7343 億美元，市盈率為-2.85，貝塔值為 0.68。該公司的 50 日移動平均價格為 8.42 美元，200 日移動平均價格為 11.11 美元。該公司的速動比率為 11.43，流動比率為 11.43，債務與股本比率為 0.14。</p>
<p>Replimune Group（納斯達克代碼：REPL - 獲取免費報告）最近一次公佈財報是在 5 月 22 日，報告顯示該季度每股收益（EPS）為-0.82 美元，低於分析師共識預期的-0.75 美元，差額為-0.07 美元。去年同期，該公司每股收益為-0.25 美元。分析師預測 Replimune Group, Inc.在當前年度的每股收益將為-2.97 美元。</p>
<h2>內部人士下注</h2>
<p>在其他新聞中，內部人士 Konstantinos Xynos 於 5 月 20 日出售了 7,952 股該公司的股票，交易價格為每股 8.06 美元，總交易額為 64,093.12 美元。出售後，該內部人士現在直接持有 146,933 股公司股票，價值 1,184,279.98 美元。這筆交易代表其持股比例下降了 5.13%。該交易已在證券交易委員會的法律文件中披露，相關信息可在 SEC 網站上找到。此外，首席會計官 Andrew Schwendenman 於 5 月 20 日出售了 3,287 股公司的股票，交易價格為每股 8.05 美元，總交易額為 26,460.35 美元。出售後，首席會計官現在直接持有 68,284 股公司的股票，價值 549,686.20 美元。這筆交易使其持股比例下降了 4.59%。該出售的披露信息可以在這裏找到。過去 90 天內，內部人士已出售 74,907 股公司股票，價值 603,655 美元。公司內部人士持有 8.80% 的股票。</p>
<h2>機構投資者對 Replimune Group 的看法</h2>
<p>機構投資者和對沖基金最近調整了對該公司的持股。Price T Rowe Associates Inc. MD 在第四季度將其在 Replimune Group 的持股增加了 11.0%。Price T Rowe Associates Inc. MD 現在持有該公司 10,962,883 股股票，價值 132,761,000 美元，此前在上個季度又購買了 1,083,633 股。Redmile Group LLC 在第四季度將其在 Replimune Group 的持股增加了 2.6%。Redmile Group LLC 現在持有該公司 4,905,527 股股票，價值 59,406,000 美元，此前在此期間又購買了 124,344 股。先鋒集團在第一季度將其在 Replimune Group 的持股增加了 6.6%。先鋒集團現在持有該公司 3,833,033 股股票，價值 37,372,000 美元，此前在此期間又購買了 237,185 股。Tang Capital Management LLC 在第四季度將其在 Replimune Group 的持股增加了 125.0%。Tang Capital Management LLC 現在持有該公司 2,700,000 股股票，價值 32,697,000 美元，此前在上個季度又購買了 1,500,000 股。最後，RTW Investments LP 在第四季度將其在 Replimune Group 的持股增加了 82.1%。RTW Investments LP 現在持有該公司 2,065,010 股股票，價值 25,007,000 美元，此前在此期間又購買了 931,223 股。對沖基金和其他機構投資者持有該公司 92.53% 的股票。</p>
<h2>Replimune Group 公司簡介</h2>
<p>（獲取免費報告）</p>
<p>Replimune Group, Inc.是一家臨牀階段的生物技術公司，專注於開發溶瘤免疫療法以治療癌症。該公司的專有腫瘤定向溶瘤免疫療法產品候選者旨在激活免疫系統對抗癌症。其主要產品候選者 RP1 是一種選擇性複製的 HSV-1 版本，表達 GALV-GP R(-) 和人類 GM-CSF，目前正在進行針對多種實體腫瘤的 I/II 期臨牀試驗；並已完成針對皮膚鱗狀細胞癌的 II 期臨牀試驗。</p>
<h2>精選故事</h2>
<ul>
<li>我們更看好的五隻股票比 Replimune Group 更好</li>
<li>現在可以購買的 2 只金融科技股票和 1 只應避免的股票</li>
<li>英特爾的轉機可能是無人關注的最佳投資</li>
<li>使用 MarketBeat 股息收益計算器</li>
<li>3 只將從金色圓頂中獲利的防禦類股票</li>
<li>什麼是 SEC 文件？</li>
<li>ASML 股票可能是這個價格下最安全的芯片投資</li>
</ul>
<p><em>此即時新聞提醒由敍述科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快和最準確的報道。此故事在發佈前已由 MarketBeat 的編輯團隊審核。如對該故事有任何問題或意見，請發送電子郵件至 contact@marketbeat.com。</em></p>
<h2>你現在應該投資 1,000 美元在 Replimune Group 嗎？</h2>
<p>在考慮 Replimune Group 之前，你需要聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其向客户推薦的股票。MarketBeat 已經識別出五隻頂級分析師悄悄建議客户現在購買的股票，以便在更廣泛的市場注意到之前……而 Replimune Group 並不在名單上。</p>
<p>雖然 Replimune Group 目前在分析師中獲得了買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>在這裏查看這五隻股票</p>

REPL

<p>Replimune Group（納斯達克代碼：REPL）股價下跌 5.9%，至 8.82 美元，交易量較平均水平下降 91%。分析師們的觀點不一，HC Wainwright 將其目標價上調至 22 美元，而摩根大通則上調至 18 美元，儘管共識評級仍為 “買入”，平均目標價為 19.43 美元。該公司報告的季度每股收益為（0.82 美元），未能達到預期。內部人士最近出售了股份，機構投資者持有 92.53% 的股份。Replimune 專注於開發用於癌症治療的溶瘤免疫療法</p>

<p>Replimune Group, Inc. (NASDAQ:REPL - Get Free Report) traded down 5.9% during trading on Friday . The company traded as low as $8.91 and last traded at $8.82. 86,686 shares changed hands during mid-day trading, a decline of 91% from the average session volume of 931,113 shares. The stock had previously closed at $9.37.</p>
<div class="lb-trans"><p>Replimune Group, Inc.（納斯達克代碼：REPL - 獲取免費報告）在週五的交易中下跌了 5.9%。該公司的股價最低曾達到 8.91 美元，最後交易價為 8.82 美元。在午盤交易中，共成交了 86,686 股，較平均交易量 931,113 股下降了 91%。該股票此前收盤價為 9.37 美元。</p>
</div><p>Get <strong>Replimune Group</strong> alerts:</p>
<div class="lb-trans"><p>獲取 <strong>Replimune Group</strong> 的提醒：</p>
</div><h2>Analysts Set New Price Targets</h2>
<div class="lb-trans"><h2>分析師設定新的價格目標</h2>
</div><p>A number of equities analysts have recently commented on the company. HC Wainwright boosted their price target on Replimune Group from $21.00 to $22.00 and gave the stock a &#34;buy&#34; rating in a report on Thursday, February 13th. JPMorgan Chase &amp; Co. raised their price objective on shares of Replimune Group from $16.00 to $18.00 and gave the company an &#34;overweight&#34; rating in a research note on Wednesday, February 26th. Seven investment analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company's stock. According to MarketBeat, the company has a consensus rating of &#34;Buy&#34; and an average price target of $19.43.</p>
<div class="lb-trans"><p>多位股票分析師最近對該公司發表了評論。HC Wainwright 將 Replimune Group 的價格目標從 21.00 美元上調至 22.00 美元，並在 2 月 13 日的報告中給予該股票 “買入” 評級。摩根大通將 Replimune Group 的股票目標價從 16.00 美元上調至 18.00 美元，並在 2 月 26 日的研究報告中給予該公司 “增持” 評級。七位投資分析師對該股票給予了買入評級，一位分析師給予了強烈買入評級。根據 MarketBeat 的數據，該公司的共識評級為 “買入”，平均價格目標為 19.43 美元。</p>
</div><p><strong>Check Out Our Latest Analysis on REPL</strong></p>
<div class="lb-trans"><p><strong>查看我們對 REPL 的最新分析</strong></p>
</div><h2>Replimune Group Stock Down 6.8%</h2>
<div class="lb-trans"><h2>Replimune Group 股票下跌 6.8%</h2>
</div><p>The stock has a market capitalization of $673.43 million, a PE ratio of -2.85 and a beta of 0.68. The company's fifty day moving average price is $8.42 and its 200-day moving average price is $11.11. The company has a quick ratio of 11.43, a current ratio of 11.43 and a debt-to-equity ratio of 0.14.</p>
<div class="lb-trans"><p>該股票的市值為 6.7343 億美元，市盈率為-2.85，貝塔值為 0.68。該公司的 50 日移動平均價格為 8.42 美元，200 日移動平均價格為 11.11 美元。該公司的速動比率為 11.43，流動比率為 11.43，債務與股本比率為 0.14。</p>
</div><p>Replimune Group (NASDAQ:REPL - Get Free Report) last announced its earnings results on Thursday, May 22nd. The company reported ($0.82) EPS for the quarter, missing analysts' consensus estimates of ($0.75) by ($0.07). During the same quarter last year, the firm earned ($0.25) EPS. Analysts forecast that Replimune Group, Inc. will post -2.97 earnings per share for the current year.</p>
<div class="lb-trans"><p>Replimune Group（納斯達克代碼：REPL - 獲取免費報告）最近一次公佈財報是在 5 月 22 日，報告顯示該季度每股收益（EPS）為-0.82 美元，低於分析師共識預期的-0.75 美元，差額為-0.07 美元。去年同期，該公司每股收益為-0.25 美元。分析師預測 Replimune Group, Inc.在當前年度的每股收益將為-2.97 美元。</p>
</div><h2>Insiders Place Their Bets</h2>
<div class="lb-trans"><h2>內部人士下注</h2>
</div><p>In other news, insider Konstantinos Xynos sold 7,952 shares of the firm's stock in a transaction dated Tuesday, May 20th. The stock was sold at an average price of $8.06, for a total transaction of $64,093.12. Following the sale, the insider now directly owns 146,933 shares in the company, valued at $1,184,279.98. This trade represents a 5.13% decrease in their position. The transaction was disclosed in a legal filing with the Securities &amp; Exchange Commission, which is available at the SEC website. Also, CAO Andrew Schwendenman sold 3,287 shares of the company's stock in a transaction on Tuesday, May 20th. The stock was sold at an average price of $8.05, for a total transaction of $26,460.35. Following the sale, the chief accounting officer now directly owns 68,284 shares of the company's stock, valued at $549,686.20. The trade was a 4.59% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 74,907 shares of company stock worth $603,655 in the last ninety days. 8.80% of the stock is owned by company insiders.</p>
<div class="lb-trans"><p>在其他新聞中，內部人士 Konstantinos Xynos 於 5 月 20 日出售了 7,952 股該公司的股票，交易價格為每股 8.06 美元，總交易額為 64,093.12 美元。出售後，該內部人士現在直接持有 146,933 股公司股票，價值 1,184,279.98 美元。這筆交易代表其持股比例下降了 5.13%。該交易已在證券交易委員會的法律文件中披露，相關信息可在 SEC 網站上找到。此外，首席會計官 Andrew Schwendenman 於 5 月 20 日出售了 3,287 股公司的股票，交易價格為每股 8.05 美元，總交易額為 26,460.35 美元。出售後，首席會計官現在直接持有 68,284 股公司的股票，價值 549,686.20 美元。這筆交易使其持股比例下降了 4.59%。該出售的披露信息可以在這裏找到。過去 90 天內，內部人士已出售 74,907 股公司股票，價值 603,655 美元。公司內部人士持有 8.80% 的股票。</p>
</div><h2>Institutional Investors Weigh In On Replimune Group</h2>
<div class="lb-trans"><h2>機構投資者對 Replimune Group 的看法</h2>
</div><p>Institutional investors and hedge funds have recently modified their holdings of the company. Price T Rowe Associates Inc. MD lifted its holdings in Replimune Group by 11.0% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 10,962,883 shares of the company's stock worth $132,761,000 after buying an additional 1,083,633 shares during the last quarter. Redmile Group LLC increased its holdings in shares of Replimune Group by 2.6% in the fourth quarter. Redmile Group LLC now owns 4,905,527 shares of the company's stock valued at $59,406,000 after purchasing an additional 124,344 shares during the period. Vanguard Group Inc. increased its holdings in shares of Replimune Group by 6.6% in the first quarter. Vanguard Group Inc. now owns 3,833,033 shares of the company's stock valued at $37,372,000 after purchasing an additional 237,185 shares during the period. Tang Capital Management LLC raised its stake in shares of Replimune Group by 125.0% during the fourth quarter. Tang Capital Management LLC now owns 2,700,000 shares of the company's stock worth $32,697,000 after purchasing an additional 1,500,000 shares during the last quarter. Finally, RTW Investments LP lifted its holdings in shares of Replimune Group by 82.1% in the 4th quarter. RTW Investments LP now owns 2,065,010 shares of the company's stock valued at $25,007,000 after buying an additional 931,223 shares during the period. Hedge funds and other institutional investors own 92.53% of the company's stock.</p>
<div class="lb-trans"><p>機構投資者和對沖基金最近調整了對該公司的持股。Price T Rowe Associates Inc. MD 在第四季度將其在 Replimune Group 的持股增加了 11.0%。Price T Rowe Associates Inc. MD 現在持有該公司 10,962,883 股股票，價值 132,761,000 美元，此前在上個季度又購買了 1,083,633 股。Redmile Group LLC 在第四季度將其在 Replimune Group 的持股增加了 2.6%。Redmile Group LLC 現在持有該公司 4,905,527 股股票，價值 59,406,000 美元，此前在此期間又購買了 124,344 股。先鋒集團在第一季度將其在 Replimune Group 的持股增加了 6.6%。先鋒集團現在持有該公司 3,833,033 股股票，價值 37,372,000 美元，此前在此期間又購買了 237,185 股。Tang Capital Management LLC 在第四季度將其在 Replimune Group 的持股增加了 125.0%。Tang Capital Management LLC 現在持有該公司 2,700,000 股股票，價值 32,697,000 美元，此前在上個季度又購買了 1,500,000 股。最後，RTW Investments LP 在第四季度將其在 Replimune Group 的持股增加了 82.1%。RTW Investments LP 現在持有該公司 2,065,010 股股票，價值 25,007,000 美元，此前在此期間又購買了 931,223 股。對沖基金和其他機構投資者持有該公司 92.53% 的股票。</p>
</div><h2>Replimune Group Company Profile</h2>
<div class="lb-trans"><h2>Replimune Group 公司簡介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（獲取免費報告）</p>
</div><p>Replimune Group, Inc, a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma.</p>
<div class="lb-trans"><p>Replimune Group, Inc.是一家臨牀階段的生物技術公司，專注於開發溶瘤免疫療法以治療癌症。該公司的專有腫瘤定向溶瘤免疫療法產品候選者旨在激活免疫系統對抗癌症。其主要產品候選者 RP1 是一種選擇性複製的 HSV-1 版本，表達 GALV-GP R(-) 和人類 GM-CSF，目前正在進行針對多種實體腫瘤的 I/II 期臨牀試驗；並已完成針對皮膚鱗狀細胞癌的 II 期臨牀試驗。</p>
</div><h2>Featured Stories</h2>
<div class="lb-trans"><h2>精選故事</h2>
</div><ul>
<li>Five stocks we like better than Replimune Group</li>
<li>2 Fintech Stocks to Buy Now and 1 to Avoid</li>
<li>Intel’s Turnaround May Be the Best Bet No One’s Watching</li>
<li>Using the MarketBeat Dividend Yield Calculator</li>
<li>3 Defense Stocks That Will Profit From a Golden Dome</li>
<li>What is a SEC Filing?</li>
<li>ASML Stock Might Be the Safest Chip Play at This Price</li>
</ul>
<div class="lb-trans"><ul>
<li>我們更看好的五隻股票比 Replimune Group 更好</li>
<li>現在可以購買的 2 只金融科技股票和 1 只應避免的股票</li>
<li>英特爾的轉機可能是無人關注的最佳投資</li>
<li>使用 MarketBeat 股息收益計算器</li>
<li>3 只將從金色圓頂中獲利的防禦類股票</li>
<li>什麼是 SEC 文件？</li>
<li>ASML 股票可能是這個價格下最安全的芯片投資</li>
</ul>
</div><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞提醒由敍述科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快和最準確的報道。此故事在發佈前已由 MarketBeat 的編輯團隊審核。如對該故事有任何問題或意見，請發送電子郵件至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Replimune Group Right Now?</h2>
<div class="lb-trans"><h2>你現在應該投資 1,000 美元在 Replimune Group 嗎？</h2>
</div><p>Before you consider Replimune Group, you'll want to hear this.</p>
<div class="lb-trans"><p>在考慮 Replimune Group 之前，你需要聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Replimune Group wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其向客户推薦的股票。MarketBeat 已經識別出五隻頂級分析師悄悄建議客户現在購買的股票，以便在更廣泛的市場注意到之前……而 Replimune Group 並不在名單上。</p>
</div><p>While Replimune Group currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然 Replimune Group 目前在分析師中獲得了買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在這裏查看這五隻股票</p>
</div>

Replimune Group（NASDAQ:REPL）股價下跌 5.9% - 現在是否應該賣出？